Samuel Moser

Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell–mediated B-cell cytotoxicity

Ekkehard Mössner, Peter Brünker, Samuel Moser et al. · Blood · 2010 · 929 citations · Full text

Target Expression, Generation, Preclinical Activity, and Pharmacokinetics of the BCMA-T Cell Bispecific Antibody EM801 for Multiple Myeloma Treatment

Anja Seckinger, Jose Antonio Delgado, Samuel Moser et al. · Cancer Cell · 2017 · 305 citations · Full text

Hematological Malignancy, Cancer Immunosurveillance, Multiple Myeloma Treatment +8

Modulation of therapeutic antibody effector functions by glycosylation engineering: Influence of Golgi enzyme localization domain and co‐expression of heterologous β1, 4‐<i>N</i>‐acetylglucosaminyltransferase III and Golgi α‐mannosidase II

Claudia Ferrara, Peter Brünker, Tobias Suter et al. · Biotechnology and Bioengineering · 2006 · 298 citations

Localization Domain, Glycobiology, Molecular Biology +18

Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines

Christian Klein, Inja Waldhauer, Valeria Nicolini et al. · OncoImmunology · 2017 · 271 citations · Full text

Effects of pre-anthesis drought, nitrogen fertilizer rate, and variety on grain yield, yield components, and harvest index of tropical maize

Samuel Moser, B. Feil, Sansern Jampatong et al. · Agricultural Water Management · 2005 · 202 citations

Crop Production, Engineering, Drought +8